AC-101 is a novel RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC). This multi-center, open-label clinical trial will evaluate the safety ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback